Vanessa Bartges
Endocrinology, Diabetes & Metabolism · Erie, PANPI 1508571191
Payments from drug & device makers
Across 147 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$640
- Lilly USA, LLC$440
- Novo Nordisk$438
- Amgen$216
- Cequr Corporation$173
- Medtronic$141
- plus $854 from 16 others
What the payments were for
- Food & beverage$2,901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 42 | $640 |
| Lilly USA, LLC | 22 | $440 |
| Novo Nordisk | 27 | $438 |
| Amgen | 10 | $216 |
| Cequr Corporation | 1 | $173 |
| Medtronic | 2 | $141 |
| Bayer | 6 | $120 |
| AbbVie | 4 | $104 |
| Amneal Pharmaceuticals LLC | 5 | $88 |
| Abbott | 5 | $83 |
| Recordati_rare_diseases_inc. | 4 | $82 |
| Boehringer Ingelheim | 3 | $65 |
| Antares Pharma, Inc. | 3 | $52 |
| Acella Pharmaceuticals, LLC | 2 | $43 |
| Amryt Pharma Holdings Ltd | 2 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Chiesi USA, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Nevro Corp. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$173
- DEXCOM G7 GSS (161)$120
- MINIMED 780G$112
How this compares
$2,901 in reported general payments places this provider in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $70,562 |
| JardianceEmpagliflozin | 20 | $27,364 |
| TrulicityDulaglutide | 18 | $26,410 |
| MounjaroTirzepatide | 20 | $24,638 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,966 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $2,078 |
| Metformin Hcl ErMetformin Hcl | 15 | $460 |
| Atorvastatin Calcium | 22 | $448 |
| Levothyroxine Sodium | 26 | $330 |
| Repaglinide | 11 | $326 |
| Metformin Hcl | 31 | $293 |
| Glimepiride | 13 | $133 |
| Glipizide ErGlipizide | 12 | $102 |
| Lisinopril | 12 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $438 | $70,56257 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $440 | $51,04838 claims |
| Boehringer IngelheimJardiance | $65 | $27,36420 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $88 | $33026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Erie
- Luis AparicioErie$69K
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.